Premium
Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate‐specific antigen: A case report
Author(s) -
Kinebuchi Yoshiaki,
Noguchi Wataru,
Irie Kyoko,
Nakayama Tsuyoshi,
Kato Haruaki,
Nishizawa Osamu
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01616.x
Subject(s) - medicine , carcinoembryonic antigen , prostate specific antigen , prostate cancer , urology , prostate , chromogranin a , neuroendocrine differentiation , gastroenterology , cancer , oncology , immunohistochemistry
A 62‐year‐old man had been treated with combined androgen blockade due to cT2bN1M0 prostate cancer, and his serum prostate‐specific antigen (PSA) levels decreased and remained under the level of 0.5 ng/mL during therapy. Approximately 40 months after the initial therapy, difficulty on urination and constipation developed gradually, and serum carcinoembryonic antigen (CEA) and pro‐gastrin‐releasing peptide (ProGRP) levels were high at this point. He underwent transrectal and transurethral biopsy of the prostate, which revealed adenocarcinoma positive for CEA and chromogranin A. He received palliative pelvic irradiation, and oral estramustine phosphate and etoposide combined therapy. Tumor markers decreased and clinical symptoms improved for several months. The patient died of encephalopathy of unknown etiology approximately 11 months after the relapse.